Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Has Consensus Price Target of $5.00

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has earned an average recommendation of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $5.00.

Several equities analysts have recently weighed in on the company. Citigroup reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, August 19th. HC Wainwright reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, September 21st.

Institutional Trading of Citius Pharmaceuticals

A hedge fund recently bought a new stake in Citius Pharmaceuticals stock. BlackRock Inc. purchased a new position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned approximately 0.25% of Citius Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Trading Up 2.2%

Shares of Citius Pharmaceuticals stock opened at $0.50 on Thursday. The company has a fifty day simple moving average of $0.60 and a 200-day simple moving average of $0.63. The stock has a market cap of $13.71 million, a price-to-earnings ratio of -0.30 and a beta of 1.00. Citius Pharmaceuticals has a 12-month low of $0.47 and a 12-month high of $2.19. The company has a current ratio of 0.84, a quick ratio of 0.40 and a debt-to-equity ratio of 0.08.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. On average, equities analysts forecast that Citius Pharmaceuticals will post -2.03 EPS for the current fiscal year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc (NASDAQ: CTXR) is a specialty pharmaceutical company focused on developing and commercializing products for oncology and critical care. The company’s pipeline has included therapies intended to address unmet medical needs in hospital and cancer-care settings.

Citius’ lead oncology product is LYMPHIR (denileukin diftitox-cxdl), an FDA-approved treatment for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy.